Cravatt Benjamin 4

What Happened
Benjamin Cravatt, a director of Alnylam Pharmaceuticals (ALNY), was granted a derivative award covering 4,393 shares on June 1, 2026. The Form 4 reports an acquisition price of $0.00 and classifies the transaction as an award/grant (derivative). This is a compensation-related option award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-01; filing date: 2026-06-03.
• Transaction type: Award/Grant of a derivative (stock option) — 4,393 shares; reported acquisition price $0.00.
• Vesting: The award vests one-third on each of the first, second and third anniversaries of the grant date (per footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Filed within a typical Form 4 window (no late filing flag indicated).

Context
This was a standard equity compensation grant to a director. As a derivative (stock option) award, it does not represent an immediate cash purchase or sale; value will depend on future stock performance and the option’s exercise terms. Such grants are common for director compensation and do not by themselves signal a personal buy or sell decision.